Annual EBIT
-$163.34 M
-$23.67 M-16.95%
December 31, 2023
Summary
- As of February 7, 2025, AUTL annual earnings before interest & taxes is -$163.34 million, with the most recent change of -$23.67 million (-16.95%) on December 31, 2023.
- During the last 3 years, AUTL annual EBIT has risen by +$2.92 million (+1.76%).
- AUTL annual EBIT is now -1036.16% below its all-time high of -$14.38 million, reached on September 30, 2016.
Performance
AUTL EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$71.39 M
-$23.34 M-48.58%
September 30, 2024
Summary
- As of February 7, 2025, AUTL quarterly earnings before interest & taxes is -$71.39 million, with the most recent change of -$23.34 million (-48.58%) on September 30, 2024.
- Over the past year, AUTL quarterly EBIT has dropped by -$37.96 million (-113.55%).
- AUTL quarterly EBIT is now -1697.23% below its all-time high of -$3.97 million, reached on December 31, 2022.
Performance
AUTL Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$199.93 M
-$30.53 M-18.02%
September 30, 2024
Summary
- As of February 7, 2025, AUTL TTM earnings before interest & taxes is -$199.93 million, with the most recent change of -$30.53 million (-18.02%) on September 30, 2024.
- Over the past year, AUTL TTM EBIT has dropped by -$38.09 million (-23.53%).
- AUTL TTM EBIT is now -562.96% below its all-time high of -$30.16 million, reached on March 31, 2019.
Performance
AUTL TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
AUTL EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -16.9% | -113.5% | -23.5% |
| 3 y3 years | +1.8% | -76.3% | -58.1% |
| 5 y5 years | -553.1% | -76.3% | -58.1% |
AUTL EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -16.9% | at low | -1697.2% | at low | -66.3% | at low |
| 5 y | 5-year | -17.5% | +1.8% | -1697.2% | at low | -66.3% | at low |
| alltime | all time | -1036.2% | +1.8% | -1697.2% | at low | -563.0% | at low |
Autolus Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$71.39 M(+48.6%) | -$199.93 M(+18.0%) |
| Jun 2024 | - | -$48.05 M(+43.7%) | -$169.40 M(+4.7%) |
| Mar 2024 | - | -$33.43 M(-29.0%) | -$161.84 M(-0.9%) |
| Dec 2023 | -$163.34 M(+17.0%) | -$47.07 M(+15.2%) | -$163.34 M(+35.8%) |
| Sep 2023 | - | -$40.86 M(+0.9%) | -$120.24 M(-4.9%) |
| Jun 2023 | - | -$40.49 M(+16.0%) | -$126.45 M(-5.4%) |
| Mar 2023 | - | -$34.92 M(+779.2%) | -$133.68 M(-4.3%) |
| Dec 2022 | -$139.66 M(-0.9%) | -$3.97 M(-91.6%) | -$139.66 M(-12.0%) |
| Sep 2022 | - | -$47.07 M(-1.4%) | -$158.72 M(+5.1%) |
| Jun 2022 | - | -$47.72 M(+16.7%) | -$151.03 M(+5.7%) |
| Mar 2022 | - | -$40.90 M(+77.5%) | -$142.84 M(+1.4%) |
| Dec 2021 | -$140.93 M | -$23.04 M(-41.5%) | -$140.93 M(-13.7%) |
| Sep 2021 | - | -$39.38 M(-0.4%) | -$163.34 M(-2.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$39.53 M(+1.4%) | -$166.67 M(+0.3%) |
| Mar 2021 | - | -$38.99 M(-14.2%) | -$166.16 M(+0.3%) |
| Dec 2020 | -$166.26 M(+19.6%) | -$45.44 M(+6.4%) | -$165.73 M(+6.0%) |
| Sep 2020 | - | -$42.71 M(+9.5%) | -$156.32 M(+4.8%) |
| Jun 2020 | - | -$39.02 M(+1.2%) | -$149.23 M(+1.2%) |
| Mar 2020 | - | -$38.56 M(+7.0%) | -$147.41 M(+6.0%) |
| Dec 2019 | -$139.01 M(+455.8%) | -$36.03 M(+1.1%) | -$139.01 M(+35.0%) |
| Sep 2019 | - | -$35.62 M(-4.3%) | -$102.98 M(+52.9%) |
| Jun 2019 | - | -$37.20 M(+23.4%) | -$67.36 M(+123.4%) |
| Mar 2019 | - | -$30.16 M | -$30.16 M |
| Dec 2018 | -$25.01 M(-56.5%) | - | - |
| Sep 2018 | -$57.53 M(+145.7%) | - | - |
| Sep 2017 | -$23.42 M(+62.9%) | - | - |
| Sep 2016 | -$14.38 M | - | - |
FAQ
- What is Autolus Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Autolus Therapeutics?
- What is Autolus Therapeutics annual EBIT year-on-year change?
- What is Autolus Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Autolus Therapeutics?
- What is Autolus Therapeutics quarterly EBIT year-on-year change?
- What is Autolus Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Autolus Therapeutics?
- What is Autolus Therapeutics TTM EBIT year-on-year change?
What is Autolus Therapeutics annual earnings before interest & taxes?
The current annual EBIT of AUTL is -$163.34 M
What is the all time high annual EBIT for Autolus Therapeutics?
Autolus Therapeutics all-time high annual earnings before interest & taxes is -$14.38 M
What is Autolus Therapeutics annual EBIT year-on-year change?
Over the past year, AUTL annual earnings before interest & taxes has changed by -$23.67 M (-16.95%)
What is Autolus Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of AUTL is -$71.39 M
What is the all time high quarterly EBIT for Autolus Therapeutics?
Autolus Therapeutics all-time high quarterly earnings before interest & taxes is -$3.97 M
What is Autolus Therapeutics quarterly EBIT year-on-year change?
Over the past year, AUTL quarterly earnings before interest & taxes has changed by -$37.96 M (-113.55%)
What is Autolus Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of AUTL is -$199.93 M
What is the all time high TTM EBIT for Autolus Therapeutics?
Autolus Therapeutics all-time high TTM earnings before interest & taxes is -$30.16 M
What is Autolus Therapeutics TTM EBIT year-on-year change?
Over the past year, AUTL TTM earnings before interest & taxes has changed by -$38.09 M (-23.53%)